ATE433977T1 - Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate - Google Patents

Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate

Info

Publication number
ATE433977T1
ATE433977T1 AT04721905T AT04721905T ATE433977T1 AT E433977 T1 ATE433977 T1 AT E433977T1 AT 04721905 T AT04721905 T AT 04721905T AT 04721905 T AT04721905 T AT 04721905T AT E433977 T1 ATE433977 T1 AT E433977T1
Authority
AT
Austria
Prior art keywords
tetrahydropyrimido
perfluoro
pyrimidine
derivatives
substituted
Prior art date
Application number
AT04721905T
Other languages
English (en)
Inventor
Alistair Lochead
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE433977T1 publication Critical patent/ATE433977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04721905T 2003-03-21 2004-03-19 Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate ATE433977T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290728A EP1460076A1 (de) 2003-03-21 2003-03-21 Substituierte 8-Perfluoro-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-on-Derivate
PCT/EP2004/004013 WO2004083210A1 (en) 2003-03-21 2004-03-19 SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES

Publications (1)

Publication Number Publication Date
ATE433977T1 true ATE433977T1 (de) 2009-07-15

Family

ID=32799141

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04721905T ATE433977T1 (de) 2003-03-21 2004-03-19 Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate

Country Status (26)

Country Link
US (2) US7217715B2 (de)
EP (2) EP1460076A1 (de)
JP (1) JP4572194B2 (de)
KR (1) KR101070075B1 (de)
CN (1) CN100368412C (de)
AR (1) AR053082A1 (de)
AT (1) ATE433977T1 (de)
AU (1) AU2004222105B2 (de)
BR (1) BRPI0408605A (de)
CA (1) CA2517774C (de)
CY (1) CY1109345T1 (de)
DE (1) DE602004021572D1 (de)
DK (1) DK1608653T3 (de)
EA (1) EA009198B1 (de)
ES (1) ES2328812T3 (de)
HK (1) HK1088893A1 (de)
IL (1) IL170634A (de)
MX (1) MXPA05010112A (de)
NO (1) NO20054331L (de)
NZ (1) NZ542224A (de)
PL (1) PL1608653T3 (de)
PT (1) PT1608653E (de)
SI (1) SI1608653T1 (de)
TW (1) TWI322809B (de)
WO (1) WO2004083210A1 (de)
ZA (1) ZA200507192B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460076A1 (de) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituierte 8-Perfluoro-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-on-Derivate
US8771552B2 (en) * 2005-06-23 2014-07-08 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
US9708735B2 (en) 2005-06-23 2017-07-18 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
JP4277826B2 (ja) * 2005-06-23 2009-06-10 住友電気工業株式会社 窒化物結晶、窒化物結晶基板、エピ層付窒化物結晶基板、ならびに半導体デバイスおよびその製造方法
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1790649A1 (de) 2005-11-21 2007-05-30 Sanofi-Aventis Substituierte bicyclische Pyrimidone Derivaten
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1939187A1 (de) * 2006-12-20 2008-07-02 Sanofi-Aventis Substituierte Heteroaryl-Pyridopyrimidon-Derivate
EP2138495A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate
EP2138488A1 (de) 2008-06-26 2009-12-30 sanofi-aventis 4-(Pyridin-4-yl)-1H-[1,3,5]Triazin-2-one-Verbindungen als GSK3-beta Hemmer zur Behandlung neurodegenerative Erkrankungen
EP2138498A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte trizyklische Derivate gegen neurodegenerative Erkrankungen
EP2138485A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte N-Oxid-Pyrazin-Derivate
EP2138492A1 (de) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidin-4-one-Derivate
EP2138494A1 (de) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Alkylpyrimidin-4-one-Derivate
EP2138493A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidon-Derivate
MX2012000103A (es) 2009-07-02 2012-05-22 Sanofi Sa Nuevos derivados de 1,2,3,4-tetrahidro-pirimido (1,2-a) pirimidin-6-ona, su preparacion y su uso farmaceutica.
US8815853B2 (en) 2010-12-23 2014-08-26 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136482A1 (de) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer
JP2001270884A (ja) * 2000-03-23 2001-10-02 Mitsubishi-Tokyo Pharmaceuticals Inc ピリミドン誘導体
EP1184383A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(Heteroaryl)alkyl] und 9-[(Aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on Derivate
WO2002018386A1 (en) * 2000-09-01 2002-03-07 Sanofi-Synthelabo 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES
EP1460076A1 (de) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituierte 8-Perfluoro-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-on-Derivate

Also Published As

Publication number Publication date
JP2006520766A (ja) 2006-09-14
EP1460076A1 (de) 2004-09-22
AR053082A1 (es) 2007-04-25
US20070191384A1 (en) 2007-08-16
CA2517774A1 (en) 2004-09-30
PL1608653T3 (pl) 2009-12-31
JP4572194B2 (ja) 2010-10-27
TW200505922A (en) 2005-02-16
DE602004021572D1 (de) 2009-07-30
ES2328812T3 (es) 2009-11-18
CN100368412C (zh) 2008-02-13
ZA200507192B (en) 2007-03-28
US7217715B2 (en) 2007-05-15
KR20050111781A (ko) 2005-11-28
US20060035910A1 (en) 2006-02-16
CY1109345T1 (el) 2014-07-02
CN1784407A (zh) 2006-06-07
PT1608653E (pt) 2009-09-07
KR101070075B1 (ko) 2011-10-04
EA009198B1 (ru) 2007-12-28
NZ542224A (en) 2008-11-28
MXPA05010112A (es) 2006-05-17
AU2004222105A1 (en) 2004-09-30
HK1088893A1 (en) 2006-11-17
CA2517774C (en) 2011-10-18
US7393853B2 (en) 2008-07-01
SI1608653T1 (sl) 2009-12-31
BRPI0408605A (pt) 2006-03-07
DK1608653T3 (da) 2009-10-05
WO2004083210A1 (en) 2004-09-30
EP1608653B1 (de) 2009-06-17
IL170634A (en) 2012-02-29
NO20054331L (no) 2005-12-21
TWI322809B (en) 2010-04-01
EA200501311A1 (ru) 2006-04-28
NO20054331D0 (no) 2005-09-20
AU2004222105B2 (en) 2010-03-04
EP1608653A1 (de) 2005-12-28

Similar Documents

Publication Publication Date Title
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO2017014I1 (no) 6-acetyl-8-cyclopentyl-5-metyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-on
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
CY2014018I2 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
DK1611131T3 (da) Pyrazolopyridin-derivater
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
DK1381363T3 (da) Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE420066T1 (de) Amidoacetonitrilderivate
ATE352550T1 (de) Chinazolinderivate
ATE395345T1 (de) Imidazol-4-yl-ethynyl-pyridin-derivate
NO20043565L (no) Heteroaryl-substituerte 2-pyridinyl- og 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater.
ATE326467T1 (de) Imidazo 1,2-aöpyridine
DK1534707T3 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
DK1682129T3 (da) N-thiazol-2-ylbenzamidderivater
ATE449064T1 (de) Amidoacetonitrilderivate
NL1025932C2 (nl) 3-Azabicycloó3.2.1!octaanderivaten.
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
NL1027301A1 (nl) Tropaanderivaten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608653

Country of ref document: EP